Get Premium Data for Cyber Monday: Up to 55% Off InvestingProCLAIM SALE

AstraZeneca PLC (AZNs)

BATS Europe
Currency in SEK
1,485.00
+24.50(+1.68%)
Closed
AZNs Scorecard
Full Analysis
Net income is expected to grow this year
Fair Value
Day's Range
1,485.001,485.00
52 wk Range
1,266.251,795.75
Key Statistics
Edit
Bid/Ask
1,488.50 / 1,472.00
Prev. Close
1,460.5
Open
1,485
Day's Range
1,485-1,485
52 wk Range
1,266.25-1,795.75
Volume
77
Average Volume (3m)
736
1-Year Change
11.13%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AZNs Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
17,704.40
Upside
+66.18%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period
Show more

AstraZeneca PLC Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Employees
89900

Compare AZNs to Peers and Sector

Metrics to compare
AZNs
Peers
Sector
Relationship
P/E Ratio
32.4x15.6x−0.7x
PEG Ratio
3.310.210.00
Price/Book
5.2x2.4x2.6x
Price / LTM Sales
4.1x2.0x3.2x
Upside (Analyst Target)
-21.3%46.6%
Fair Value Upside
Unlock14.3%7.4%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 4.19
Dividend Yield
2.07%
Industry Median 1.27%
Annualised payout
30.7359
Paid unevenly
5-Years Growth
-
Growth Streak

FAQ

What Is the AstraZeneca PLC (AZNs) Stock Price Today?

The AstraZeneca PLC stock price today is 1,485.00

What Stock Exchange Does AstraZeneca PLC Trade On?

AstraZeneca PLC is listed and trades on the BATS Europe stock exchange.

What Is the Stock Symbol for AstraZeneca PLC?

The stock symbol for AstraZeneca PLC is "AZNs."

Does AstraZeneca PLC Pay Dividends? What’s The Current Dividend Yield?

The AstraZeneca PLC dividend yield is 2.19%.

What Is the AstraZeneca PLC Market Cap?

As of today, AstraZeneca PLC market cap is 2.30T.

What is AstraZeneca PLC Earnings Per Share?

The AstraZeneca PLC EPS is 4.19.

What Is the Next AstraZeneca PLC Earnings Date?

AstraZeneca PLC will release its next earnings report on 05 Feb 2025.

From a Technical Analysis Perspective, Is AZNs a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.